̽»¨ºÏ¼¯

The launch ensures MS patients in the US currently benefitting from Gilenya, or generic fingolimod, can access appropriate patient support services alongside the bioequivalent, non-generic, TASCENSO ODT.

Joseph A. Ferraro joins ̽»¨ºÏ¼¯ as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary in February 2023 and is responsible for managing ̽»¨ºÏ¼¯â€™s global legal and compliance operations.

The state-of-the-art facility contains development and manufacturing space across multiple cleanrooms for the dedicated production of CGMP-grade pDNA for clinical and commercial-phase supply

The new Case Management Service addresses challenges associated with delivering advanced therapies to patients by providing supply chain oversight from program start to finish.

Mr. Zayas will be responsible for ̽»¨ºÏ¼¯â€™s North American biologics operations. He will serve on the Executive Leadership Team, reporting directly to President & CEO, Alessandro Maselli.

̽»¨ºÏ¼¯ and Ethicann announced a development and license agreement to develop Ethicann’s clinical drug pipeline using ̽»¨ºÏ¼¯â€™s proprietary Zydis® orally disintegrating tablet technology.

̽»¨ºÏ¼¯ and Sarepta sign an agreement to manufacture delandistrogene moxeparvovec, Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy.

̽»¨ºÏ¼¯ today announced a $12 million expansion program to increase biologics CGMP analytical capabilities at its flagship facility in Kansas City, Missouri.

The new facility will be one of the largest in the world with multi-product, segregated suites designed to support autologous and allogeneic cell therapy manufacturing.